E10030

DRUG5 trials

Sponsors

Ophthotech Corporation, National Eye Institute (NEI)

Conditions

Age-Related Macular DegenerationAge-related Macular DegenerationVon Hippel-Lindau Syndrome

Phase 1

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

CompletedNCT00569140

Ophthotech CorporationAge-related Macular Degeneration

Start: 2007-12-31End: 2008-12-31Target: 18Updated: 2024-02-21

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

CompletedNCT02859441

National Eye Institute (NEI)Von Hippel-Lindau Syndrome

Start: 2017-01-23End: 2019-07-09Updated: 2021-11-01

Phase 3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

TerminatedNCT01940887

Ophthotech CorporationAge-Related Macular Degeneration

Start: 2014-05-31End: 2017-09-30Updated: 2024-10-31

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

TerminatedNCT01940900

Ophthotech CorporationAge-Related Macular Degeneration

Start: 2013-08-31End: 2016-12-31Updated: 2024-10-30

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

TerminatedNCT01944839

Ophthotech CorporationAge-Related Macular Degeneration

Start: 2013-08-31End: 2016-12-31Updated: 2024-10-30